Consumer Guide,Oncopeptides AB (STO:ONCO) share price: SEK1.39

Understanding the Oncopeptides share price is crucial for investors looking to gauge the performance and potential of this biotechnology company. Oncopeptides AB (publ), a pharmaceutical company focused on developing targeted therapies for hematological diseases, is publicly traded on Nasdaq Stockholm Small Cap under the ticker symbol ONCO. Since its listing on February 22, 2017, the stock has experienced various fluctuations, making a detailed examination of its stock price essential.

The Oncopeptides share price is subject to market dynamics, company-specific news, and broader industry trends. As of recent data, the price has been observed around 1.461 SEK, with some reports indicating a +1.63% change in the past 24 hours. Other sources show the Oncopeptides AB (ONCO:STO) traded at 1.43, highlighting the dynamic nature of its valuation. Investors often look to Oncopeptides share price prediction, Oncopeptides share price forecast, and Oncopeptides share price target to inform their investment strategies. For instance, analysts have projected an average one-year price target for ONCO at 2.695 SEK, with forecasts ranging from a low of 2.668 SEK to a high of 2.774 SEK. Another forecast suggests an average one-year price target of 2.86 kr, with a range from 2.83 kr to 2.94 kr. There's even an indication of a potential upside of +101.29% based on analysts' average price targets.

Delving into the Oncopeptides Stock Price History reveals patterns and trends that can offer valuable insights. For example, historical data points show recent prices such as 1.548 SEK and 1.550 SEK on specific dates in March 2026, and further back, 1.3990 and 1.4240 in early April 2026. The Oncopeptides AB (publ) (ONCO.ST) stock price has seen a 52 Week Change of -30.14%, with a 52 Week Low recorded around 1.33 on April 13, 2026, and a 52 Week High of 4.63 on July 1, 2026. The current stock is trading at 1.3520 -0.0130, reflecting a slight decrease.

The company's financial health and operational progress are often reflected in its stock price. Oncopeptides AB is involved in the development of targeted therapies, and news regarding clinical trials, regulatory approvals, or the publication of financial reports, such as the Oncopeptides publishes year-end report 2025, can significantly influence investor sentiment and the stock value. The market cap of Oncopeptides AB (publ) is reported as SEK 529.685m, with Shares Outstanding at 381.15M and an EPS (TTM) of -1.02. The average volume is 2.62M, and the market cap is 1.11B.

Understanding the context of Oncopeptides AB (publ) (ONCO.ST) within the broader market is also important. Its peers and key competitors are part of the competitive landscape in the biotechnology sector. While specific competitor mentions like Nasdaq ZYME and Saab stock appear in related searches, the primary focus for investors remains on Oncopeptides AB. The company's Articles of association and details about its Share issues are also available for those seeking a deeper understanding of its corporate structure and financial activities.

In summary, the Oncopeptides share price is a multifaceted indicator influenced by market performance, analyst expectations, and the company's ongoing development in the pharmaceutical sector. Investors keen on tracking this stock should regularly consult up-to-date financial data, news releases, and historical prices to make informed decisions. The stock symbol for Oncopeptides AB is ONCO, and it is listed on Nasdaq Stockholm. The Oncopeptides AB (publ) (OM:ONCO) stock price and Oncopeptides AB (STO:ONCO) share price are key metrics to monitor for those invested in or considering investing in this company.